-
公开(公告)号：WO2020215155A8
公开(公告)日：2020-10-29
申请号：PCT/CA2020/050535
申请日：2020-04-23
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： LI, Sze-wan , BRAY, Mark Robert
IPC: C07D413/10 , A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15
Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.
-
Patent Agency Ranking2.发明申请
公开(公告)号：WO2021226707A1
公开(公告)日：2021-11-18
申请号：PCT/CA2021/050645
申请日：2021-05-10
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： BRAY, Mark R. , LI, Sze-wan
IPC: C07D495/04 , A61K31/194 , A61K31/4365 , A61P35/00 , C07C59/255
Abstract: A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.
-
公开(公告)号：WO2016065461A1
公开(公告)日：2016-05-06
申请号：PCT/CA2015/051024
申请日：2015-10-09
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： LAUFER, Radoslaw , NG, Grace , BROKX, Richard , PAULS, Heinz W. , LI, Sze-wan , MASON, Jacqueline M. , BRAY, Mark R.
IPC: C07D487/04 , A61K31/519 , A61P29/00 , A61P35/00 , A61P37/06
CPC classification number: A61K31/519 , A61K45/06 , C07D487/04
Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
Abstract translation: 本发明是由结构式（I）表示的化合物：（I）; 或其药学上可接受的盐。 这里提供了变量的值。 还包括药物组合物，其包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂以及用结构式（I）的化合物治疗患有癌症的受试者的方法。
-
公开(公告)号：EP3959209A1
公开(公告)日：2022-03-02
申请号：EP20795605.3
申请日：2020-04-23
Applicant: University Health Network
Inventor： LI, Sze-wan , BRAY, Mark Robert
IPC: C07D413/10 , A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15
-
公开(公告)号：EP3212652A1
公开(公告)日：2017-09-06
申请号：EP15855932.8
申请日：2015-10-09
Applicant: University Health Network
Inventor： LAUFER, Radoslaw , NG, Grace , BROKX, Richard , PAULS, Heinz W. , LI, Sze-wan , MASON, Jacqueline M. , BRAY, Mark R.
IPC: C07D487/04 , A61K31/519 , A61P29/00 , A61P35/00 , A61P37/06
CPC classification number: A61K31/519 , A61K45/06 , C07D487/04
Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
Abstract translation: 本发明是由结构式（I）表示的化合物：（I）; 或其药学上可接受的盐。 这里提供了变量的值。 还包括包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂的药物组合物以及用结构式（I）的化合物治疗患有癌症的个体的方法。
-
6.发明公开
公开(公告)号：EP4149946A1
公开(公告)日：2023-03-22
申请号：EP21803607.7
申请日：2021-05-10
Applicant: University Health Network
Inventor： BRAY, Mark R. , LI, Sze-wan
IPC: C07D495/04 , A61K31/194 , A61K31/4365 , A61P35/00 , C07C59/255
-
-
-
-
-
Search Results
6
records
(took 0.022 seconds)
